logo
logo
AI + EXCLUSIVE DATA

AI analyzes funding data you can't access anywhere else

Our proprietary AI monitors 15,000+ companies and identifies which funded companies need YOUR specific solution right now.

10-25 personalized leads daily • 92% average intent score • Smart feed technology
Start with:
✓Flexible Plans • $39/mo or $29/mo annual
✓AI + real-time funding intelligence
✓Never see duplicates in your feed
INDUSTRY FIRST

Oncopep Completes $11 Million Series D Financing To Continue Clinical Trials And Advance Pipeline Development

Dec 09, 2021•over 3 years ago

Amount Raised

$11 Million

Round Type

series d

Cambridge

Description

OncoPep, Inc., a developer of transformative immunotherapeutics, announced $11 million in Series D funding. The Series D was led by Tera Science and Kukje Pharma with participation from SX Company and CrystalBioScience.

Company Information

Company

Onco Pep, Inc

Location

Cambridge, Maryland, United States

About

OncoPep, Inc. is developing novel immunotherapeutics to prevent the progression of cancer, extend survival, and restore the quality of life of patients. OncoPep's lead program, PVX-410, is an investigational, multi-peptide therapeutic vaccine being evaluated in treating multiple myeloma and triple-negative breast cancer by stimulating an immune response against cancer cells. SOURCE OncoPep, Inc.

FundzWatch™ Score

64
Medium Activity

Funding Insights

Based on industry data
Tech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech